Magenta Q2 loss narrows to $16.9M, cash $207.8M; FDA clinical hold on MGTA-117

Dianthus Therapeutics, Inc. /DE/

2022-Q2 EPS reported -$0.67

Net loss $16.9M in Q2 2021 vs $19.1M in Q2 2020; cash $207.8M sufficient into Q3 2023.
MGTA-117 IND clinical hold: FDA requires additional bioassay to inform dose escalation; toxicology/manufacturing not at issue.
Enrollment complete for Phase 2 MGTA-145 + plerixafor in multiple myeloma; final data expected Q4 2021.
Plans to initiate Phase 2 MGTA-145 trial in sickle cell disease in Q4 2021 with bluebird bio.
Director Mike Bonney resigned Aug 3; no disagreement; board reduced to 9; Alison Lawton named Chair.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael W. Bonney

Director

DNTH · Dianthus Therapeutics, Inc. /DE/

Effective: 2021-08-03
Filed: August 5, 2021, 7:59 PM ET

On August 3, 2021, Michael W. Bonney notified the Company of his intent to resign from the Company’s Board of Directors (the “Board”) and its committees effective August 3, 2021, to focus on his newly expanded role as Executive Chair of Alnylam Pharmaceuticals, Inc.

Role change

Alison F. Lawton

Chair of the Board

DNTH · Dianthus Therapeutics, Inc. /DE/

Effective: 2021-08-04
Filed: August 5, 2021, 7:59 PM ET

Alison F. Lawton, currently a member of the Board, was appointed Chair of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael W. Bonney resigned as Director at Dianthus Therapeutics, Inc. /DE/.

Action: resigned
Role: Director

Exact text from the filing

On August 3, 2021, Michael W. Bonney notified the Company of his intent to resign from the Company’s Board of Directors (the “Board”) and its committees effective August 3, 2021, to focus on his newly expanded role as Executive Chair of Alnylam Pharmaceuticals, Inc.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alison F. Lawton was appointed as Chair of the Board at Dianthus Therapeutics, Inc. /DE/.

Action: appointed
Role: Chair of the Board

Exact text from the filing

Alison F. Lawton, currently a member of the Board, was appointed Chair of the Board

View on SEC.gov

Dianthus Therapeutics, Inc. /DE/ filing history →

Source: SEC EDGAR

accession 0001193125-21-237056

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.